Tuesday, November 17, 2026

GET OUR FREE E-NEWSLETTER

“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Search

Pharmaceutical Industry Corruption is Systemic and Structural

Pharmaceutical Industry Corruption is Systemic and Structural

An empirical review published in the Journal of Law, Medicine & Ethics describes corruption within the pharmaceutical industry as a systemic, industry-wide problem rather than the isolated misconduct of a few individuals. The review’s author, Marc Rodwin, drew on data and case studies from the Organization for Economic Co-operation and Development (OECD) to examine the extent of corruption across the pharmaceutical industry.1

“The OECD case studies, and Kohler and colleagues’ article, offer an alternative narrative to those who contend that bribes are an exception committed by a few bad actors who deviate from the prevailing industry norms,” Rodwin wrote.1

The findings implicated every major pharmaceutical company in cross-national bribery schemes, as well as corrupt practices involving marketing, regulatory authorization, procurement, prescribing, and professional conduct. The schemes extended across multiple levels of the industry and involved sales representatives, physicians, nurses, corporate executives, and politicians.1 2

Pharma Profits Far Exceed Regulatory Fines and Civil Penalties

Rodwin argued that existing laws, regulatory policies, and industry self-regulation have proven insufficient to curb pharmaceutical corruption, in part because the financial incentives outweigh the potential consequences. As he explained, “the profits from illegal and ethically questionable behavior far exceed regulatory fines and civil penalties.”2

Pharmaceutical Companies Found to Disguise Payments, Falsify Documents

OECD case studies demonstrated that bribes were often disguised as payments for legitimate business transactions, even to the point of generating false invoices. Other bribes were disguised as legitimate commercial transactions but with heavily inflated rates, allowing for illegal benefits to remain hidden within reported transactions. To hide the identities of those who received payments, pharmaceutical companies “transferred funds to shell companies, misrepresented financial transactions, and falsified documents in records and audits.” Companies disguised other bribes as payments for services to third-party vendors, charitable contributions to philanthropic foundations, or funding for clinical research.1

Bribes to Professional Include Watches, Vacations, and Luxury Goods

Companies also characterized bribes to individuals as fees for speaking, consulting, marketing, or other professional expenses. The OECD case studies found that in addition to cash payment, bribes were found to include luxury goods such as cameras, jewelry, electronics, watches, shopping vouchers, wine, or family vacations.2

Financial Disclosure Policies Only Normalize Corruption, Author States

While financial disclosure policies such as the Sunshine Act and the Anti Kickback Act have brought some corruption to light and helped to trigger reforms, Rodwin believes that this only normalizes bribery and enhances public acceptability for the practice. He also highlights the blaring conflict of interest that compromise choices.

Rodwin writes:

Bribery is routine and widespread in the international pharmaceutical industry… Transparency policies that require disclosure of payments to physicians … are grossly inadequate tools. Such policies assume the information reported will be truthful and accurate while parties employing bribes or engaging in other corruption typically falsify data they reveal … The key problem is that financial ties create conflicts of interest that compromise choices and disclosure of information does not cure the conflict of interest.1

Research Group Outlines Widespread Corruption Involving over 3,000 Pharmaceutical Companies

A 2021 Public Citizen Health Research Group (PCHRG) analyzed pharmaceutical company civil and criminal settlement agreements between 1991 and 2021 involving over 3, 230 pharmaceutical companies. Common violations included overcharging government health programs, unlawful drug promotion, kickbacks and bribery, monopoly practice and antitrust violations, and concealing research data. In the analyzed 30-year timespan PCHRG found 482 settlement agreements yielding over $62 billion in penalties. Corruption involved over 234 companies.1

In that 30-year timespan PCHRG found the following:

    • 482 settlement agreements yielding over $62 billion in penalties
    • Corruption involving over 234 companies
    • Companies with the largest payouts included Abbott, Eli Lilly, GlaxoSmith Kline, Johnson & Johnson, Merck, and Pfizer. Some had more than one settlement
    • Penalties ranged from a low of $650 million to a high of $8.344 billion

Frequently, companies continue to engage in illegal conduct after settling civil and criminal prosecutions. It is clear that, even after the financial penalties they’re forced to pay, it is still a profitable model.1

Big Chemical and Pharmaceutical Industries Have Their Roots in Ideology and Corruption

Corruption and bribery have been part of chemical and pharmaceutical industry culture from the beginning. In the 19th century, the United States was home to many traditional schools that offered courses in health and healing modalities, such as homeopathy, osteopathy and herbal and Chinese medicine. In the second decade of the 20th century, that all changed when petroleum giant John D. Rockefeller realized that pharmaceutical products could be made utilizing chemicals and oil byproducts and waste.

Wanting to maximize his corporate profits, Rockefeller and Andrew Carnegie partnered with the American Medical Association and commissioned a man named Abraham Flexner, was an educator and not a physician, to “assess” the quality of 155 medical schools in the U.S. and Canada.  After a 17 month evaluation of medical schools, The Flexner Report was published in 1910 commissioned by the Carnegie Foundation.3

The 1910 Flexner Report Targeted Homeopathy as “Unscientific Quakekry”

Flexner presented his report on medical schools to Congress and severely condemned holistic healing modalities, calling them “unscientific quackery.” He maintained that medical schools must base their curriculum on the allopathic medical model and laboratory science together with clinical experience using the medical model.

After the Flexner Report was published and publicized, medical schools offering homeopathy which refused to pivot to the allopathic/pharmaceutical-based model, were denied funding and forced to close. A 2025 systematic review comparing effectiveness and safety of homeopathic versus allopathic interventions found the non-inferiority of homeopathic remedies and a superior safety profile when compared to antibiotics and other prescription drugs.3

Based on the Flexner Report’s conclusions, Rockefeller poured hundreds of millions of dollars into medical schools and universities under the condition that they exclusively teach allopathic and pharmaceutical-based medicine. Pharmaceutical companies still fund and influence medical school textbooks, although they are rarely written openly under a corporate name.4

The heavily skewed Flexner Report, as well as the binding of medical education directly to the allopathic medical model and corporate funding gave birth to the institutional corruption that still plagues the pharmaceutical industry, medical school education and the practice of medicine today.5

Evidence-Based Medicine An “Illusion”

Additional studies and whistleblowers have revealed the pharmaceutical industry’s corruption begins long before a pharmaceutical product is put on the market. Pharmaceutical companies have faced scrutiny for manipulating research results to understate potential a drug or vaccine’s risks, overstating benefits, and obscuring findings that could undermine a pharmaceutical product’s marketability. Author Richard Sears writes:

“As detailed in the current review, pharmaceutical industry corruption is vast in scope… These practices are so common that one researcher has called evidence-based medicine an ‘illusion.’”2


If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.

Click here to view References:

1 Rodwin M A. Probing the prevalence of pharmaceutical corruption. Journal of Law, Medicine & Ethics 2026.
2 Sears R. Pharmaceutical industry corruption is structural, systemic, and profitable, new review finds. Mad in America Sept. 14, 2026.
3
4
5

Leave a Reply

Your email address will not be published. Required fields are marked *

Search in Archive

Search in Site

To search in site, type your keyword and hit enter

Search
The Vaccine Reaction
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.